Loading mutual fund details…
Mirae Asset Healthcare Fund -Regular Growth is an equity scheme managed by Mirae Asset Mutual Fund. Over rolling three-year windows since inception, investors earned a median compounded return of 18.18%, with the bottom and top quartiles at 15.89% and 21.34% respectively. It has ranked in the top half of its category for 4 of the last 7 reported years. Risk-adjusted return (Sharpe ratio) is 0.00. The total expense ratio is 2.04% on assets of ₹2,939Cr. The fund is currently managed by Mr. Tanmay Mehta, appointed within the last year.
Lower is better.
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
| Scheme | AMC | AUM | TER | 3Y |
|---|
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -12.44% | 0.11% | 16.38% | 37.54% | 63.35% | 75.3% |
| 3Y | 12.52% | 15.89% | 18.18% | 21.34% | 27.62% | 100.0% |
| 5Y | 13.67% | 14.88% | 16.44% | 18.57% | 22.61% | 100.0% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.
Does the fund get worse as it gets bigger? Each dot is one historical manager-tenure: AUM at tenure-end vs alpha delivered during that tenure.
Correlation is too weak to confirm or rule out capacity-driven alpha decay. Re-evaluate as more manager-tenure data accumulates.
Each dot is one manager-tenure: X = AUM at tenure end, Y = alpha during that tenure. Connecting line in chronological order. Pearson r measures the linear relationship between AUM and alpha across the historical record. n = 2 data points.
| 5Y |
|---|
| Star |
|---|
| UTI Healthcare Fund - Regular Plan - Growth Option | UTI Mutual Fund | ₹1,144 Cr | 2.30% | +25.58% | +13.65% | 3★ |
| SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH | SBI Mutual Fund | ₹4,323 Cr | 1.90% | +24.26% | +15.05% | 3★ |
| Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | Aditya Birla Sun Life Mutual Fund | ₹901 Cr | 2.27% | +22.88% | +12.34% | 3★ |
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | Tata Mutual Fund | ₹1,325 Cr | 2.21% | +21.66% | +13.09% | 3★ |
| DSP Healthcare Fund - Regular Plan - Growth | DSP Mutual Fund | ₹3,142 Cr | 2.12% | +21.24% | +13.81% | 3★ |
| ITI Pharma and Healthcare Fund - Regular Plan - Growth Option | ITI Mutual Fund | ₹230 Cr | 4.84% | +19.12% | — | 3★ |
| quant Healthcare Fund - Growth Option - Regular Plan | Quant Mutual Fund | ₹351 Cr | 2.47% | — | — | 2★ |
| LIC MF Healthcare Fund-Regular Plan-Growth | LIC Mutual Fund | ₹85 Cr | 2.44% | — | — | 2★ |
| Kotak Healthcare Fund - Regular Plan - Growth Option | Kotak Mahindra Mutual Fund | ₹496 Cr | 2.54% | — | — | 2★ |
| WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth | WhiteOak Capital Mutual Fund | ₹603 Cr | 2.57% | — | — | 2★ |